[Asia Economy Reporter Park Jihwan] Macrogen announced on the 17th that it has acquired a patent related to the detection and diagnosis of cancer stem cells.
The name of this patented technology is a cancer stem cell-specific biomarker. It pertains to a composition for detecting cancer stem cells present in glioma, glioblastoma, anaplastic glioblastoma, meningioma, pituitary adenoma, and neurofibroma.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
